Bacillus anthracis: Medical issues of biologic warfare

Pharmacotherapy

Volumn 19, Issue 6, 1999, Pages 690-701

  Ibrahim, Khalid H ^a   Brown, Gigi ^a,b   Wright, David H ^a,b   Rotschafer, John C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; CIPROFLOXACIN; DOXYCYCLINE; IMMUNOLOGICAL ADJUVANT; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL VIRULENCE; BIOLOGICAL WARFARE; DISEASE TRANSMISSION; GASTROINTESTINAL SYMPTOM; HEALTH CARE SYSTEM; HUMAN; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOGENESIS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN MANIFESTATION; UNITED STATES; VACCINATION;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL VACCINES; BIOLOGICAL WARFARE; HUMANS;

EID: 0032997362     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.9.690.31543     Document Type: Review

References (50)

1. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;208:399-411.
2. Bartlett JG. Update in infectious diseases. Ann Intern Med 1998;129:468-9.
3. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlosk anthrax outbreak of 1979. Science 1994;266:1202-7.
4. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biologic warfare agent. Arch Intern Med 1998;158:429-34.
5. Burnett JW. Anthrax. Cutis 1991;48:113-14.
6. McKendrick DRA. Anthrax and its transmission to humans. Cent Afr J Med 1980;26:126-9.
7. Farrar WE. Anthrax: virulence and vaccines. Ann Intern Med 1994;121:379-80.
8. Hanna P. Anthrax pathogenesis and host response. Curr Topics Microbiol Immunol 1988;225:13-35.
9. Mims CA, Playfair JH, Roitt IM, Wakehn D, Williams R, Anderson RM, eds. Medical microbiology. St. Louis: Mobsy 1993:314.
10. Orent W. Winning a deadly war. Atlanta Journal-Constitution December 13, 1998.
11. Tortora GJ, Funke BR, Case CL, eds. Microbiology, an introduction. Redwood, CA: Benjamin/Cummings, 1992:72-3, 287, 566.
12. Gillert DJ. Pentagon plans mass anthrax vaccinations. American Forces Press Service, 1997. Available from URL: http:/Avww.dtic.mil/afps/news/9712167.html.
13. Christie AB. The clinical aspects of anthrax. Postgrad Med J 1973;49:565-70.
14. Zilinskas RA. Iraq's biologic weapons: the past as future? JAMA 1997;278:418-24.
15. Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997;65:5171-5.
16. Hambleton P, Carman JA, Melling J. Anthrax: the disease in relation to vaccines. Vaccine 1984;2:125-32.
17. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7.
18. Lew D. Bacillus anthracis. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. New York: Churchill Livingstone, 1995:1885-9.
19. Micromedex Inc. Anthrax: warfare agent, vol 94, exp 11-97. In: Gelman CR, Rumack BH, Hutchison TA, eds. Drugdex system. Englewood, CO: Micromedex.
20. Abramowicz M, ed. The choice of antibacterial drugs. Med Lett Drugs Ther 1996;38:25-30.
21. Anonymous. Bioterrorism alleging use of anthrax and interim guidelines for management - United States, 1998. MMWR 1999;48:69-74.
22. Friedlander AM, Welkos SL, Pitt ML. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-42.
23. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hygiene 1956;54:28-36.
24. Ivins BE, Welkos SL, Knudson GB, Little SF. Immunization against anthrax with aromatic compound-dependent (Aro-)mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect Immun 1990;58:303-8.
25. Turnbull PCB. Anthrax vaccines: past, present, and future. Vaccine 1991;9:533-9.
26. Nass M. Anthrax vaccine safety and efficacy - USA. ProMED-mail post. January 2, 1998. Available from URL: http://www. healthnet.org/programs/promed-hma/9801/msg00021.html.
27. Couzin J. Preparing to counter an invisible adversary. US News February 22, 1999.
28. Darlow HM, Pride NB. Serological diagnosis of anthrax. Lancet 1969;2:430.
29. Doganay M, Aygen B. Diagnosis: cutaneous anthrax. Clin Infect Dis 1997;25:725.
30. Turnbull PCB, Kramer JM. Bacillus. In: Murray PR, ed. Manual of clinical microbiology. Washington, DC: ASM Press, 1995:349-56.
31. Anonymous. Anthrax vaccination program facts. Air Force News: News Service. December 16, 1997. Available from URL: http://www.af.mil/news/Dec1997/n19971216_971604.html.
32. Anonymous. Accelerated anthrax vaccination program to enhance force protection announced. White House Press Release. March 3, 1998. Available from URL: http://www. defenselink.mil/news/Mar1998/b03031998_bt094.html.
33. Lightfoot NF, Scott RJD, Turnbull PCB. Antimicrobial susceptibility of Bacillus anthracis. Salisbury Med Bull Suppl 1990;68:95-8.
34. Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol 1996;44:155-60.
35. Ivins B, Fellows P, Pin L, et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 1995;13:1779-84.
36. Turnbull PCB, Leppla SH, Broster MG, Quinn CP, Melling J. Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol 1988;177:293-303.
37. Brachman PCB, Gold H, Plotkin SA, Fekety FR, Werrin M, Ingraham NR. Field evaluation of human anthrax vaccine. Am J Public Health 1962;42:632-45.
38. Shlyakhov E, Rubinstein E, Novikov I. Anthrax post-vaccinal cell-mediated immunity in humans: kinetics pattern. Vaccine 1997;15:631-6.
39. Little SF, Knudson GB. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in guinea pig. Infect Immun 1986;52:509-12.
40. Pezard C, Weber M, Sirard J, Berche P, Mock M. Protective immunity induced by toxin-deficient strains. Infect Immun 1995;63:1369-72.
41. Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect Immun 1992;60: 662-8.
42. Turnbull PCB, Broster MG, Carman JA, Manchee RJ, Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxins in humans and guinea pigs and their relevance to protective immunity. Infect Immun 1986;52:356-63.
43. Kaufmann A. Anthrax vaccine safety and efficacy - USA. ProMED-mail post. April 15, 1998. Available from URL: http://www.healthnet.org/programs/promed-hma/9804/msg00104.html.
44. Anonymous. Anthrax vaccine: alum precipitated anthrax antigens. Available from URL: http://www.gulfweb.co.uk/ vaccines/an_inst.html.
45. Presidential Advisory Committee on Gulf War Veterans' Illnesses. Anthrax and botulinum toxoid vaccines. PBS and WGBH/Frontline online. December 1996. Available from URL: http://www.pbs.org/wgbh/pages/frontline/shows/syndrome/anal ysis/vaccines.html.
46. Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect Immun 1986;54:537-42.
47. Miller J, McBride BW, Manchee RJ, Moore P, Baillie LWJ. Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Lett Appl Microbiol 1998;26:56-60.
48. Ivins BE, Welkos SL, Knudson GB, Leblanc DJ. Transposon Tn916 mutagenesis in Bacillus anthracis. Infect Immun 1998;56:176-81.
49. Department of Public Safety, State of Minnesota. Suggested response activities to anthrax incident, November 1998. St. Paul: Author, 1998.
50. Horrock N. The new terror fear: biologic weapons. US News May 5, 1998.